Research programme: coronavirus vaccines - NuGenerex Immuno-Oncology/Generex
Alternative Names: SARS vaccine - NuGenerex Immuno-Oncology/Generex; Severe Acute Respiratory Syndrome vaccine - NuGenerex Immuno-Oncology/GenerexLatest Information Update: 16 Jan 2019
At a glance
- Originator Antigen Express; Generex Biotechnology Corporation
- Class COVID-19 vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Severe acute respiratory syndrome
Most Recent Events
- 03 Feb 2012 No development reported - Preclinical for Severe acute respiratory syndrome in Canada (unspecified route)
- 03 Feb 2012 No development reported - Preclinical for Severe acute respiratory syndrome in USA (unspecified route)
- 15 Aug 2003 Antigen Express has been acquired by Generex Biotechnology Corporation